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Summary Many factors have been individually related to outcome in populations of non-small-cell lung
cancer (NSCLC) patients. Factors responsible for the outcome of an individual after surgical resection are
poorly understood. We have examined the importance of 'tumour volume' in determining prognosis ofpatients
following resection of NSCLC in a multivariate model. Cox's proportional hazard analysis was used to
determine the relative prognostic significance of stage, patient age, gender, tumour cell-type, nodal score and
estimated 'tumour volume' in 669 cases with NSCLC treated with surgical resection, ofwhich 280 had died. All
factors (except tumour cell-type, P=0.33) were individually related to survival (P<0.05). When examined
together, survival time was significantly and independently related to 'tumour volume' and stage (P<0.001),
and other factors ceased to be significant. In cases with stage I or II tumours, risk of death was found to
increase significantly with increasing estimated 'tumour volume' (23.8% relative increase in hazard of death per
doubling of 'tumour volume', 95% confidence interval 13.2-35.2%, P<0.001 stage I; P<0.006 stage II). In
cases with stage Illa tumours this factor alone was the significant prognostic variable. In conclusion, an
estimate of 'tumour volume' significantly improves prediction ofprognosis for individual NSCLC patients with
UICC stage I or II tumours.
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Non-small-cell lung carcinoma (NSCLC) accounts for about
three-quarters of all lung cancer histologies. Surgical
resection is the preferred treatment and approximately
50 000 operations are performed in the United States alone
each year (Lederle and Neiwoehner, 1995). The overall
prognosis for resected NSCLC is poor with less than a
third of patients who undergo resection alive 5 years later
(Humphrey et al., 1990). There have been reports of many
clinicopathological variables affecting prognosis of NSCLC.
These have largely been examined in a univariate manner.
They have included age, gender, TNM and other staging
classifications, histopathological cell-types, oncogene expres-
sion and tumour biomarkers (Carney, 1992; Szabo and
Mulshine, 1993).
In considering a large number of factors together
multivariate analyses are valuable for determining which
factors are independently influencing outcome and for
categorising their relative importance. In patients with
inoperable lung carcinoma multivariate analaysis has shown
the most important prognostic factors to be performance
score, stage and weight loss in the previous 6 months
(Stanley, 1980). In small-cell lung carcinoma proportional
hazard models have shown performance status, age, gender
and number of metastases to be the most significant
predictors (Albain et al., 1990; Gronowitz et al., 1990).
We have previously shown that an estimate of NSCLC
'tumour volume' has a complex relationship with age which is
dependent on patient gender and histological cell type
(Pendleton et al., 1996). In this study we examine the
importance of 'tumour volume' as a predictor of survival
after resection of NSCLC in a multivariate model including
stage, patient age, gender, histopathological tumour cell type
and nodal score.
Materials and methods
The patient group comprised 669 cases with NSCLC treated
by surgical resection between 1987 and 1992 at the Regional
Thoracic Surgical Unit for Mersey region, UK. Patients were
accepted solely on the basis of operability; age did not
contribute to the assessment or selection process. All
resections underwent thoracic nodal sampling at surgery.
Resected specimens were received in the department of
histopathology at Broadgreen Hospital, Liverpool, UK,
inflation-fixed in buffered formalin. The specimens were
then examined macroscopically by a histopathologist whose
examination included measurement of the maximum tumour
diameter in three dimensions using a Vernier calliper.
'Tumour volume' was estimated by multiplying the three
maximum dimensional measurements. Material from the
specimens was taken from representative areas for subse-
quent light microscopic examination by two histopathologists
within the department acting independently.
Each report generated from the department ofhistopathol-
ogy included the following data: identification number, date
of operation, date of birth, sex, specimens received,
description of the macroscopic and microscopic findings
including tumour site, dimensions, tumour cell type and
nodal metastasis. Cell type was reported following the World
Health Organization criteria (WHO, 1982) and nodal
metastasis by the nodal score according to TNM classifica-
tion criteria (UICC, 1987). Staging was performed according
to the criteria proposed by Mountain et al. (1993). Cases of
carcinoid, large-cell and mixed-cell-type tumours were
excluded where analysis included cell type as a variable. An
independent histopathological review of cell-type diagnosis
was performed in a random group of 90 cases (13%).
For survival analysis, zero time for each subject was
designated as the date of resection. The end point of the
follow-up period was June 1994. Certified dates and causes of
death were obtained from the National and Mersey and
Cheshire Regional Cancer Registry.
Kaplan -Meier (product-limit) estimates were computed
for the overall survival function unadjusted for any covariate
factors. A more detailed analysis to investigate which clinical
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measures were related to (predictive of) survival time was
then performed using Cox proportional hazards models (Cox,
1972). The Cox model is a semi-parametric regression model
which can be stated in the form:
hi(t) = hO(t)exp(fz)
Where h(t) is the (proportional) hazard for the ith of n
individuals at some time t, ,B represents the regression
coefficients for the matrix of independent predictor variables
z, and h. is the hazard for an individual for whom all
predictor variables have the value zero. Initially univariate
analyses were done using a single clinical measure as the only
predictor variable. Finally, a multivariate analysis was carried
out in which survival predictor variables were allowed to
enter the model in a forward stepwise manner; at each step
an additional predictor variable being added if it significantly
improved the prediction of survival. The level of significance
for entry into the model was P<0.05, and for removal was
Pk0.10.
Results
The distribution of the number of cases and 'tumour volume'
by clinicopathological variable groups is summarised in Table
I. The review of 90 randomly selected cases by an
independent histopathologist blind to the original histopatho-
logical subtyping revealed disagreement in only one case.
Of the 669 subjects 12 were lost to follow-up. The length
of follow-up ranged from 1 month to 80 months. In all 280
patients had died when the study was terminated. Cancer was
certified as the cause of death in 246 of these. Overall the
median survival was 66.0 months (95% confidence limits
50.6-81.4), the probability of survival at 2 years was 62.6%
and at 5 years was 52.0%. The distribution of 'tumour
volume' and probabilities of survival by stage, gender, cell-
type and nodal score groups is shown in Table I (columns 2
and 3).
Univariate analysis of relationships between the variables
described earlier by Cox proportional hazard is shown in
Table II. Increasing risk of death was found to be
significantly related to increased patient age at resection,
male gender and increasing TNM nodal score. Tumour cell-
type (adenocarcinoma compared with squamous cell carcino-
ma) was not significantly related to survival (P=0.33).
Tumour stage and 'tumour volume' were both very
significantly related to survival, there being an increased
risk of death with increasing 'tumour volume' and stage
group (P<0.001).
Multivariate proportional hazard analysis involving the six
variables found to be individually related to survival time
Table I Distribution ofcases, 'tumour volume' and probabilities of survival at 2 and 5 years, by age, gender, TNM nodal score, tumour cell-
type and UICC tumour stage after resection of NSCLC
Probability of
Number of Mean 'tumour volume' survival (%) at
Variable group cases (cm3) with s.e.m. 2 and 5 years
Gender
Male 445 131.4+11.4 60.0 50.8
Female 224 78.4±11.5 68.0 54.9
TNM nodal score
NO 434 108.0+10.9 71.5 60.0
Ni 115 115.2+15.5 50.6 44.7
N2 120 123.0+ 16.1 41.8 29.7
Tumour cell type
Adenocarcinoma 230 114.6± 16.5 59.4 47.7
Squamous cell 314 98.8 7.8 64.6 55.6
Large cell 44
Carcinoid 22
Mixed cell types 59
Stage
I 403 91.6+8.6 73.2 60.8
II 106 92.4+ 13.0 53.4 45.0
lIla 160 178.8+24.2 41.8 34.0
-, Calculations that were not made (see Materials and methods).
Table II Univariate Cox's proportional hazard analysis of relationship between age at resection, patient gender, TNM
nodal score, UICC stage and 'tumour volume' after resection of NSCLC
Significance ofrelationship Relative increase in hazard
Variables to survival time (95% CI)
Age at resection P=0.027 1.34% per year of increasing age (0.1-2.5%)
Gender P=0.024 28.5% males vs females (1.6-62.5%)
TNM nodal score P<0.001 85% NO vs NI (35-152%)
P<0.001 151% NO vs N2 (89-233%)
Tumour cell type P=0.330 -
Tumour stage P<0.001 76.1% stage I vs II (31.0- 137%)
P<0.001 121% stage II vs III (74.9-179%)
'Tumour volume' P<0.001 19.2% per doubling of 'tumour
volume' (12.6-26%)'Tumour volume' predicts survival in NSCLC
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indicated that, after taking account of the information
provided by 'tumour volume' and stage in combination,
age, gender, nodal score and tumour cell-type ceased to be
predictive of survival. 'Tumour volume' and stage interacted
significantly (P<0.001), indicating that the information
provided by 'tumour volume' differed according to stage.
For stage I and II tumours, risk of death rose significantly
as 'tumour volume' increased (P<0.001), the rate of increase
being indistinguishable for the two stages (P=0.54); the risk
of dying during a given period of time was increased by
23.8% (95% confidence limits 13.2-35.2%) with a doubling
of tumour volume.
For stage IIIa tumours, 'tumour volume' was unrelated to
survival (P=0.44), the fact that the tumour had reached this
advanced stage being predictive of outcome alone. Relative to
stage I and II tumour types, the risk of death associated with
a stage III tumour was estimated as being increased by 485%
(98% confidence limits 254-1250%).
Kaplan-Meier survival plots for stage I/IT and Illa
tumour stages are shown in Figure 1.
Discussion
Surgery is the treatment of choice for NSCLC although
patients presenting with localised disease suitable for curative
resection account for only 15% of all cases. For those treated
with surgery, two-thirds will suffer recurrent disease within 5
years (Splinter, 1992; Martini, 1990; Shields, 1993). This has
led to the examination of many clinicopathological variables
that predict prognosis.
In clinical practice UICC stage (Mountain et al., 1991) has
emerged as the single most important criterion for manage-
ment (Greenberg et al., 1987). It is those cases with stage I, II
or Illa tumours that are generally considered suitable for
surgery (Lederle and Neiwoehner, 1995). In common with
other studies (Mountain, 1993) we have found stage to be an
extremely significant independent predictor of survival, and
to supplant other factors we examined in a multivariate
model.
Within the TNM scale, the development of mediastinal
metastasis has been shown to be a critical transition affecting
survival (Wantanabe, 1991), and resectability (Mountain,
1993). This corresponds to the development of UICC stage
Illa from stage II. The results of this study support this
finding, with no factor other than being in the stage Illa
group having prognostic significance by multivariate analysis
in these cases.
Contrary to some reports (Rosenthal and Curran, 1990)
we did not find tumour cell-type to be of prognostic
significance. There may be three reasons for this difference.
Firstly, while tumour cell-type and tumour stage relationships
are reported (Teeter et al., 1987; O'Rourke et al., 1987) this
does not imply an effect on survival.
Secondly, in this study comparison was only made
between adenocarcinoma and squamous cell carcinoma, and
unlike some previous studies, infrequent cell-type groups
known to follow different courses such as large-cell and
carcinoid tumours were excluded. Thirdly, as with all studies
of measures generated from post-operative samples a
selection bias may have occurred. The cases in this study
may not necessarily be representative of the behaviour of the
population of NSCLC tumours as a whole, and the results
should rather be seen as representative only of those cases
that have presented for and been selected for thoracic
surgery.
We found age, male gender and nodal score to be
univariately related to increased risk of death. However,








Figure 1 Survival functions of resected NSCLC patients grouped
by tumour stage presented as Kaplan-Meier plots. Staging was
performed using the criteria set out by Mountain (1993). L-, stage
lIla; 0, stage II; *, stage I.
and ceased to add further predictive information in the
multivariate model. This would suggest that these factors are
important in a population sense, but are not significant when
considering an individual patient with a certain stage of
tumour. The finding that transition from stage I or II to Illa
is of great prognostic significance, while TNM nodal score is
not, indicates that this prognostic step involves more than
mediastinal metastasis, and is related to the TNM tumour
score-a function of which is tumour size. Lack of
significance of 'tumour volume' with stage Illa cases may,
however, be caused by bias against larger tumours owing to
incomplete resection.
A novel finding of this study is that 'tumour volume' is an
extremely significant independent predictor of prognosis, and
until the tumours have reached conditions for a classification
of stage Illa, appears to be the key factor, superseding the
transition from stage I to II, age, gender, tumour cell-type
and nodal metastasis.
We have previously shown that 'tumour volume' is related
in a complex manner to age, gender and tumour cell-type
(Pendleton et al., 1996). The omission of these factors from
the multivariate model with the inclusion of 'tumour volume'
indicates that they may together act to influence prognosis by
affecting the 'tumour volume'.
There has been much investigation of the prognostic
significance of molecular factors (Carney, 1992; Szabo and
Mulshine, 1993). While the inclusion of biomarker levels in a
multivariate model has been shown to increase prognostic
efficiency (Walop et al., 1990), these techniques have not
gained widespread clinical acceptance, are expensive and only
available at a limited number of sites.
Thus, we conclude that while UICC staging remains the
gold standard in prognosis and management of NSCLC, this
study shows that an estimate of 'tumour volume', an easy-to-
calculate measure that requires no specialist equipment, gives
significant prognostic information over and above that of the
UICC stage. We therefore suggest that estimation of 'tumour
volume' should be considered as part of the routine post-
operative prognostic work-up of NSCLC. Multivariate
analyses including other factors such as oncogene expression
and histopathological measures together with 'tumour
volume' in prognosis of NSCLC merit further investigation.
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